MGC Pharmaceuticals are on track to launch their dermatological product range in Europe in the third quarter of 2017 after producing a solid set of results from a final clinical trial.
Three products in the company’s DermaPlus product range were tested on 90 volunteers over a three-month period with the independent trial conducted by Dr Rok Devjak at a leading dermatological clinic in Solvenia.
According to the company the results were very positive and the latest endorsement of MGC Pharma’s claims of the medicinal and healing powers of cannabis.
The tests showed an 80% improvement in acne prone skin, 73% improvement in psoriatic plaques, 86% improvement of irritated skin and over 70% improvement in the visual appearance of redness, dryness, flaky and oily skin conditions.
Perhaps the most telling statistic was that 92% of the volunteers stated they would continue using the MGC Pharma creams they had tested.
The positive results from the clinical test mean MGC Pharma will be able to market each DermaPlus product with specific claims about its effectiveness.
Importantly, the new test results are also expected to lead to permission to use the ‘dermatologically tested’ label, in line with European Parliamentary regulations. The label denotes MGC Pharma’s products as a premium skincare range.
In a statement to the ASX, MGC Pharma stated they were on track to fully commercialise the DermaPlus range, with product sales expected to begin in the third quarter of 2017. The range will be distributed through established channels, via the company’s own eShop and new distribution agreements with pharmacy outlets throughout Europe.
MGC Pharma’s co-founder and Managing Director, Nativ Segev, said: “We are exceptionally pleased that out DermaPlus product range has demonstrated such strong results through these clinical tests. Validating the use of medicinal cannabis through rigorous clinical tests is vital to our business model and, with over 50 products still in development, these positive results give us a glimpse into the exciting potential of our product range.”
By Matt Birney
